AllianceBernstein
ALXO icon

AllianceBernstein’s ALX Oncology ALXO Stock Holding History

AllianceBernstein’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.8K Buy
+26,340
New +$47.1K ﹤0.01% 3291
2025
Q2 		– Sell
-71,730
Closed -$44.7K – 3236
2025
Q1 		$44.7K Hold
71,730
– – ﹤0.01% 3143
2024
Q4 		$120K Hold
71,730
– – ﹤0.01% 3109
2024
Q3 		$131K Hold
71,730
– – ﹤0.01% 3100
2024
Q2 		$433K Buy
71,730
+32,940
+85% +$405K ﹤0.01% 2743
2024
Q1 		$433K Sell
38,790
-1,500
-4% -$21.1K ﹤0.01% 2643
2023
Q4 		$600K Hold
40,290
– – ﹤0.01% 2520
2023
Q3 		$193K Buy
40,290
+1,710
+4% +$9.28K ﹤0.01% 2977
2023
Q2 		$290K Buy
38,580
+8,580
+29% +$56.2K ﹤0.01% 2878
2023
Q1 		$136K Buy
30,000
+1,500
+5% +$11.4K ﹤0.01% 2982
2022
Q4 		$321K Buy
28,500
+3,100
+12% +$34.8K ﹤0.01% 2843
2022
Q3 		$243K Sell
25,400
-2,400
-9% -$28K ﹤0.01% 2955
2022
Q2 		$225K Buy
27,800
+7,300
+36% +$79.5K ﹤0.01% 2987
2022
Q1 		$346K Hold
20,500
– – ﹤0.01% 2829
2021
Q4 		$441K Sell
20,500
-3,000
-13% -$129K ﹤0.01% 2796
2021
Q3 		$1.74M Hold
23,500
– – ﹤0.01% 2242
2021
Q2 		$1.28M Buy
23,500
+1,100
+5% +$65.8K ﹤0.01% 2425
2021
Q1 		$1.65M Buy
22,400
+7,600
+51% +$598K ﹤0.01% 2200
2020
Q4 		$1.28M Buy
+14,800
New +$890K ﹤0.01% 2202

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

AllianceBernstein's ALXO Position: Q2 2026 in Review

AllianceBernstein opened a new position in ALX Oncology (ALXO) in Q2 2026: 26,340 shares worth $52.8K. The stake represents ﹤0.01% of the portfolio and ranks #3291 among its holdings. This is a return to the name: AllianceBernstein previously reported a position in ALXO as recently as Q1 2025.

AllianceBernstein first reported a position in ALXO in Q4 2020 and has held it in 19 quarters since. The position peaked at $1.74M in Q3 2021. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • AllianceBernstein held 26,340 shares of ALX Oncology worth $52.8K as of Q2 2026.
  • ALX Oncology was a new AllianceBernstein position in Q2 2026.
  • ALX Oncology made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3291 holding.
  • AllianceBernstein first reported a position in ALX Oncology in Q4 2020 and has held it in 19 quarters since.
  • AllianceBernstein's ALX Oncology position peaked at $1.74M in Q3 2021.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.